Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil

Abstract

For women with breast cancer who are being treated with cyclophosphamide, methotrexate, and fluorouracil, the efficacy of dexamethasone and metoclopramide in controlling nausea and vomiting equaled or exceeded that of ondansetron.

Antiemetic Efficacy of Ondansetron and Metoclopramide, Both Combined with Corticosteroid, in Malignant Lymphoma Patients Receiving Non-Cisplatin Chemotherapy

“…This is at least as good as earlier trials where patients receiving non-cisplatin CT treated with OND alone obtained control rates form 65-82% (6)(7)(8)(9).…”

“…In cyclophosphamide and antracycline combination regimens, OND used as single antiemetic drug has proved to be superior to MCP (6,7) in treating acute nausea and emesis, and comparable to MCP combination regimens (8) and dexamethasone used as monotherapy respectively (9). In breast cancer patients receiving moderately emetogenic CT, the combination of OND and dexamethasone is significantly better than MCP and dexamethasone in the control of acute and delayed nausea and emesis over 6 courses of treatment (10).…”

Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo

“…That some of the P450 modulators examined in this study are commonly administered with cytotoxics for cancer patients [e.g. DEX as an antiemetic (Levitt et al, 1993)] should be considered more seriously by clinicians in view of these in vivo and in vitro results. Chemotherapeutic agents such as IF are commonly administered in combination regimens, involving other anti-cancer drugs and immunomodulators, and both groups of compounds have demonstrated potential to alter liver P450 profiles and enzyme levels (LeBlanc and Waxman, 1990;LeBlanc et al, 1992;Royer et al, 1996;Tapner et al, 1996).…”

Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo

“…granisetron was reported to be more potent as an anti-emetic when administered by the oral route than the intravenous route, whereas the reverse was true for ondansetron (Fitzpatrick et al, 1990). Ondansetron, the most extensively studied 5-HT3 receptor antagonist, is poorly effective in controlling mild and delayed emesis (Kris et al, 1992;Levitt et al, 1993). Furthermore, none of the currently available 5-HT3 receptor antagonists is capable of completely blocking the incidence of nausea and emesis in cancer patients.…”